Good news for the Mannkind Corporation (MNKD) this morning as they announced positive results of two late stage studies for their inhaled insulin Diabetes drug, Afrezza. According to the Mannkind website, Afrezza is “a novel, ultra rapid-acting mealtime insulin therapy in late stage clinical investigation for the treatment of adult patients with Type 1 and […]